Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli Lilly ...

Merck (NYSE:MRK) is preparing to launch a subcutaneously delivered formulation of their blockbuster cancer medication Keytruda for patient convenience as the company approaches a steep patent cliff ...

Merck (MRK) stock plummeted Tuesday after the Dow Jones stock topped Wall Street's fourth-quarter expectations, but delivered lighter-than-expected guidance for 2025. The company also withdrew its ...

Announcing better-than-expected financials for Q1 2025 on Thursday, Merck (NYSE:MRK) lowered its full-year outlook for earnings to account for various headwinds, including a $200M impact related to ...

Matthew Herper covers medical innovation — both its promise and its perils. Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales ...

Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal something retirees cannot afford to ignore. Before you chase the bigger payout, the coverage numbers behind each dividend tell ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Merck lowered its full-year profit guidance, citing a charge tied to a recent licensing deal and $200 million in estimated additional costs for tariffs implemented to date. The company said the ...

Add Yahoo as a preferred source to see more of our stories on Google. Merck KGaA's antibody-drug conjugate (ADC) Merck KGaA's antibody-drug conjugate (ADC), precemtabart tocentecan (Precem-TcT), has ...

Merck KGaA now expects sales from its life science arm—which provides R&D and CDMO services, plus key materials for partners—to land between 8.8 billion euros and 9.4 billion euros in 2025. (Merck ...